Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Tomoya Maeda,Yuho Najima,Yutaro Kamiyama,Shinji Nakao,Yukinori Ozaki,Hiroshi Nishio,Kenji Tsuchihashi,Eiki Ichihara,Yuji Miumra,Makoto Endo,Dai Maruyama,Tatsuhiro Yoshinami,Nobuyuki Susumu,Munetaka Takekuma,Takashi Motohashi,Mamoru Ito,Eishi Baba,Nobuaki Ochi,Toshio Kubo,Keita Uchino,Takahiro Kimura,Shinobu Tamura,Hitomi Nishimoto,Yasuhisa Kato,Atsushi Sato,Toshimi Takano,Shingo Yano
DOI: https://doi.org/10.1007/s10147-023-02465-0
2024-03-19
International Journal of Clinical Oncology
Abstract:Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis of pooled data was conducted, and the risk ratio with corresponding confidence intervals was calculated in the meta-analysis and summarized. Sixteen studies were included in the qualitative analysis, nine of which were examined in the meta-analysis. Although G-CSF significantly shortened the duration of neutropenia, primary prophylaxis with G-CSF did not correlate with infection-related mortality. Moreover, primary prophylaxis with G-CSF did not affect disease progression/recurrence, overall survival, or adverse events, such as musculoskeletal pain. However, evidence to support or discourage the use of G-CSF as primary prophylaxis for adult AML patients with induction therapy remains limited. Therefore, the use of G-CSF as primary prophylaxis can be considered for adult AML patients with remission induction therapy who are at a high risk of infectious complications.
oncology